Depression treatment for Jupiter — measurement-based, 45 minutes away.

RECO Health's Delray Beach campus is 32 miles south of Jupiter on I-95 — 45 minutes outside of rush hour, close enough for a resident of Abacoa or Jonathan's Landing to run IOP three days a week without disrupting work. The campus houses in-house psychiatry, protocol-driven CBT, Behavioral Activation, and Interpersonal Therapy, plus rTMS and IV ketamine on-site, so a treatment-resistant case does not require a second referral. Every plan is anchored to PHQ-9 trajectory and adjusted using measurement-based care.

Jupiter sits 32 miles north of RECO Health’s Delray Beach campus — a 45-minute run down I-95 outside of rush hour. That distance matters clinically: it is short enough for a resident of Abacoa or Jonathan’s Landing to attend intensive outpatient three days a week without upending work or family, and long enough that a stay at the Delray campus for PHP-level care creates genuine separation from the environments and relationships that maintain a depressive episode. RECO Health treats major depressive disorder, persistent depressive disorder, and treatment-resistant depression at both PHP and IOP, with in-house psychiatry and — when the clinical picture warrants — access to interventional depression care including rTMS and IV ketamine.

Diagnostic formulation and severity staging

Every admission begins with a DSM-5-TR diagnostic formulation before a medication is written or a therapy modality is assigned. The evaluation distinguishes major depressive disorder from persistent depressive disorder, bipolar II depression, adjustment disorder with depressed mood, and depression secondary to a general medical condition or active substance use. Missing bipolarity is the most consequential error in outpatient depression care: RECO’s psychiatrists screen every intake with the MDQ and probe collateral history for prior hypomanic episodes before starting an antidepressant.

Severity is anchored numerically. A baseline PHQ-9 stages the episode as mild (5-9), moderate (10-14), moderately severe (15-19), or severe (20-27). The Columbia Suicide Severity Rating Scale (C-SSRS) captures ideation intensity, plan, and intent. A basic medical workup — TSH with free T4, vitamin B12, folate, vitamin D, and a comprehensive metabolic panel — rules out thyroid disease, nutritional deficiencies, and metabolic contributors that can present as treatment-refractory depression when the primary driver is not psychiatric at all.

Level of care is matched to that formulation. PHP is appropriate for severe presentations, active suicidal ideation with plan, functional collapse, or step-down from a recent hospitalization. IOP is appropriate for moderate depression when the client is safe at home, has adequate support, and needs sustained therapeutic contact without full-day programming. Transfer between levels is driven by PHQ-9 trajectory, not by a fixed calendar.

Pharmacotherapy sequenced by evidence, not habit

First-line pharmacotherapy for major depression is an SSRI or SNRI titrated to a therapeutic dose and held there for an adequate trial. Sertraline and escitalopram are the typical starting points; venlafaxine or duloxetine are preferred when comorbid chronic pain, somatic symptoms, or prior SSRI failure informs the choice. An adequate trial means four to six weeks at target dose — not two weeks at a starter dose followed by a switch, which is how most community depression care quietly fails.

Partial responders at week six are augmented before they are switched. Aripiprazole at 2-5 mg, lithium titrated to a level of 0.6-0.8 mEq/L, or bupropion added to an SSRI all have STAR*D and subsequent evidence behind them. Quetiapine XR is used selectively where anxious distress and sleep architecture dominate. Only after a failed augmentation trial does the psychiatrist switch antidepressant class, and the reasoning is documented in the chart alongside the PHQ-9 curve.

Treatment-resistant depression is defined operationally: two adequate antidepressant trials without remission (PHQ-9 under 5). At that point the treatment plan pivots to interventional care rather than cycling through a fifth oral agent. RECO’s psychiatrists do not endorse polypharmacy that accumulates side effects without moving the score.

Evidence-based psychotherapy for depression

Therapy at RECO is delivered to protocol, not as a loose collection of techniques a clinician happens to favor. Cognitive Behavioral Therapy for depression follows the Beck manual — cognitive restructuring of automatic thoughts, behavioral experiments, and homework between sessions. Behavioral Activation is used as a standalone modality or a CBT component when anhedonia and withdrawal dominate; the client and therapist build a graded activity schedule targeting reward and mastery, not “self-care” in the wellness-app sense.

Interpersonal Therapy is offered when the depressive episode is anchored in grief, role transition — a divorce, a job loss, an empty nest, common presenting contexts in Admirals Cove and Jonathan’s Landing — or unresolved interpersonal conflict. Acceptance and Commitment Therapy is used when rigid rule-governed thinking and experiential avoidance are prominent. Motivational Interviewing supports engagement when ambivalence about treatment itself is part of the clinical picture.

For the substantial subset of depressed clients whose episodes are downstream of trauma, RECO layers in Cognitive Processing Therapy or EMDR. Treating the depression without addressing the trauma tends to produce a partial responder who relapses within months of discharge.

Escalation pathway for treatment-resistant depression

Roughly a third of clients with major depressive disorder do not remit after two adequate antidepressant trials. RECO’s escalation pathway is defined at admission, not improvised at week twelve. Repetitive transcranial magnetic stimulation is offered for insurance-eligible TRD using the standard 10 Hz protocol over the left dorsolateral prefrontal cortex — 3000 pulses per session at 120% of resting motor threshold, 36 sessions over six to nine weeks, no anesthesia, no cognitive side effects.

IV ketamine at 0.5 mg/kg infused over 40 minutes, delivered as a six-infusion induction across two to three weeks, is used when suicidality or functional collapse does not permit a six-week wait for antidepressant response. Esketamine (Spravato) is available where a REMS-monitored intranasal protocol is clinically or logistically preferred. Response to any interventional modality is tracked with PHQ-9 at every visit and Montgomery-Åsberg (MADRS) at defined intervals.

Escalation happens on a schedule. A Jupiter client who enters IOP with a PHQ-9 of 22 and remains above 15 at week six becomes a candidate for interventional consultation that same week — not a candidate for a fourth SSRI trial.

What to expect on your first visit from Jupiter

Day one is a full intake. A 90-minute psychiatric evaluation with a RECO psychiatrist covers current symptoms, timeline, prior treatment history including specific medications and doses, family psychiatric history, medical comorbidities, and substance use. A parallel biopsychosocial assessment with a master’s-level therapist maps supports, stressors, and functional impairment. PHQ-9, GAD-7, C-SSRS, and the MDQ are administered at intake and repeated on a defined cadence to drive measurement-based care.

By end of day one the client leaves with a working DSM-5-TR diagnosis, a level-of-care recommendation, and either a medication plan or a documented reason to defer starting one — for example, when active substance use has to be stabilized before an antidepressant response can be assessed. IOP schedules for Jupiter commuters are set around morning I-95 traffic where clinically feasible.

Insurance and admissions from Jupiter

RECO Health is in-network with most major commercial carriers used across Palm Beach County: Florida Blue and BCBS plans, Aetna, Cigna, UnitedHealthcare, and Humana. Admissions verifies benefits within a business day and provides a written estimate of client responsibility — deductible, coinsurance, and out-of-pocket maximum — before admission, so a family in Tequesta or Jupiter Inlet Colony is not reconciling surprise bills against a depressive episode. Interventional services including rTMS and Spravato have their own prior authorization pathways, which admissions handles directly with the payer. For clients whose depression is entangled with alcohol or opioid use, the same campus houses medical detox with CIWA- and COWS-driven protocols, so transition from detox into depression-focused PHP does not require a second intake at a second facility.

Serving residents of: Abacoa, Jupiter Inlet Colony, Tequesta, Admirals Cove, Jonathan's Landing.